Roche posts pos­i­tive PhII re­sults for bis­pe­cif­ic an­ti­body eye drug, join­ing No­var­tis in ri­val­ry with Eylea

As No­var­tis bat­tles Re­gen­eron for a piece of its block­buster Eylea fran­chise, Roche/Genen­tech $RHH­BY is com­ing up qui­et­ly with a next-gen bis­pe­cif­ic an­ti­body which post­ed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER